Mallinckrodt could owe a whopping $650M in Acthar Medicaid rebates

Mallinckrodt has already had a busy year with a $1.6 billion opioid deal in the works and the planned bankruptcy of its specialty generics unit. Now, the drugmaker has taken another hit in its fight to escape a massive Medicaid bill for its controversial H.P. Acthar Gel.